Kamada (NASDAQ:KMDA) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell?

Key Points

• Kamada Ltd. shares have fallen below their 200-day moving average, closing at $6.97, signaling potential instability in the stock price.
• Wall Street analysts remain optimistic, with a consensus rating of "Moderate Buy" and an average price target of $13.00, despite the recent stock decline.
• The company reported a quarterly EPS of $0.13, exceeding expectations, yet its revenue was significantly below the consensus estimate, indicating mixed financial performance.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report)'s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $7.03 and traded as low as $6.92. Kamada shares last traded at $6.97, with a volume of 34,115 shares.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on KMDA shares. Benchmark reissued a "buy" rating and set a $15.00 price target on shares of Kamada in a research report on Thursday, May 15th. Wall Street Zen raised Kamada from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, May 21st. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Kamada has a consensus rating of "Moderate Buy" and a consensus target price of $13.00.

Kamada Stock Performance

The stock has a 50 day moving average price of $7.38 and a two-hundred day moving average price of $7.01. The company has a market capitalization of $412.60 million, a PE ratio of 21.10, a P/E/G ratio of 0.76 and a beta of 0.89.

Kamada (NASDAQ:KMDA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.04. Kamada had a return on equity of 7.41% and a net margin of 11.22%.The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $158.59 million. Kamada has set its FY 2025 guidance at EPS. Sell-side analysts predict that Kamada Ltd. will post 0.23 earnings per share for the current year.

Institutional Investors Weigh In On Kamada

Institutional investors have recently made changes to their positions in the stock. Huntleigh Advisors Inc. acquired a new position in Kamada in the first quarter valued at about $863,000. Trexquant Investment LP acquired a new stake in Kamada during the first quarter worth approximately $82,000. Cubist Systematic Strategies LLC acquired a new stake in Kamada during the first quarter worth approximately $206,000. NewEdge Advisors LLC boosted its holdings in shares of Kamada by 119.9% in the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company's stock valued at $341,000 after purchasing an additional 28,165 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new position in shares of Kamada in the 1st quarter valued at $497,000. 20.38% of the stock is owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.